PSI ToxSIG Webinar: Beyond the looking glass - Interpreting animal welfare & behaviour by monitoring & assessing mice activity data
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
For our launch, John Whitehead presented his paper, "Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme", and Kevin Carroll presented on sample size ("Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?").
Chair: Stephen Pyke
Speaker: John Whitehead
Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme
Co-authors: Patrick Kelly, Yinghui Zhou, Nigel Stallard, Helene Thygesen, Clive Bowman
Pharmaceutical Statistics, Volume 8, Issue 4, pages 287–300, October/December 2009
Abstract | Paper+ | Slides
Speaker: Kevin J. Carroll
Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?
Pharmaceutical Statistics, Volume 8, Issue 4, pages 333–345, October/December 2009
Abstract | Paper+ | Slides
+ Papers available to view from 3rd November 2009 to 29th December 2009.
Analysing continuously collected locomotive activity data to interpret mice welfare and behaviour.
Our next journal club features two papers on the topic of Survival Analysis. For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
Hear about potential strategies to handle non-proportional hazards and delayed treatment effects from experts in the field.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
By joining our company, in this role you will apply your skills and experience in support of developing scientifically based arguments aiming to provide fair accessibility to our company’s drugs and vaccines making a real difference in patient’s lives.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.